Project Summary
This EU-funded project pioneers tailored interventions for new-onset type 1 diabetes that protect and restore beta cells while minimizing interference with the immune system. Grounded in a strong understanding of disease pathogenesis, the project aims to translate experimental findings into future clinical applications.
Work Packages:
WP1 – Re-educating antigen-presenting cells: Using vitamin D and glucocorticoids to induce tolerance in dendritic cells.
WP2 – Restoring T-cell balance: Modulating T-lymphocytes with steroid hormones to prevent destructive immune responses.
WP3 – TCR-mediated immunotherapy: Employing soluble T-cell receptors to specifically target immune cells and beta cells.
WP4 – Mucosal intervention: Testing probiotics and recombinant Lactococcus lactis carrying peptides and cytokines to restore immune tolerance.
WP5 – Beta-cell protection: Investigating how beta-cells themselves contribute to and influence immune attack.
WP6 – Pharmacogenetics: Identifying patient genetic profiles predicting responsiveness to steroid-based interventions.
WP7 & WP8 – Training and Management: Building expertise and coordinating consortium efforts.
Consortium:
The project unites 11 leading European academic institutions with 3 innovative SMEs (ActoGeniX NV, DanDrit Biotech A/S, and Immunocore Ltd), bringing together expertise in diabetes, immunology, and translational technology.